Skip to main content
SpringerLink
Log in

The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE (PCI—CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) have demonstrated the clinical efficacy and safety of clopidogrel for the treatment of patients with non-ST-segment elevation acute coronary syndromes (ACS), including those undergoing percutaneous coronary intervention. In these settings, clopidogrel significantly reduces the risk of atherothrombotic events, with relative risk reductions of 20–30% (absolute risk reduction 1.9–3.0%). Health economic evaluations based on data from these studies conducted in Europe and the United States have clearly demonstrated the costeffectiveness of clopidogrel in combination with aspirin compared with aspirin alone for the management of ACS. Within-trial evaluations based on CURE and PCI—CURE data showed that treatment with clopidogrel on top of standard therapy reduced the cost of initial hospitalisation as well as the total cost associated with hospitalisations. Long-term economic analyses based on the CURE study demonstrate that clopidogrel is cost saving in the Netherlands and that the cost per life-year gained (LYG) in other European countries is between €549 and €5048. In the United States, the cost per LYG for clopidogrel has been assessed at US$6173 on the basis of CURE, US$5910 for PCI—CURE and US$3685 for CREDO, all of which are considerably lower than that associated with common cardiovascular benchmarks. The results are robust and consistent across different countries using varying costing strategies and estimates of survival. In conclusion, these data demonstrate that clopidogrel in combination with aspirin for the management of ACS is both clinically effective and cost-effective in this setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Fig. 1
Table VIII
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002; 13 Suppl. 1: 1–6

    Article  PubMed  Google Scholar 

  2. Herbert J-M, Savi P, Maffrand J-P. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. Eur Heart J 1999; 1 Suppl. A: A31–A40

    CAS  Google Scholar 

  3. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891–6

    PubMed  CAS  Google Scholar 

  4. Herbert JM, Dol F, Bernat A, et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80: 512–18

    PubMed  CAS  Google Scholar 

  5. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998; 98: 2461–9

    Article  PubMed  CAS  Google Scholar 

  6. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502

    Article  Google Scholar 

  7. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI—CURE study. Lancet 2001; 358: 527–33

    Article  PubMed  CAS  Google Scholar 

  8. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20

    Article  PubMed  CAS  Google Scholar 

  9. Braunwald E, Antman E, Beasley J, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction — 2002: summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106: 1893–900

    Article  PubMed  Google Scholar 

  10. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809–40

    Article  PubMed  Google Scholar 

  11. Lamy A, Chrolavicius S, Gafni A, et al. The costeffectiveness of the use of clopidogrel in acute coronary syndromes based upon the CURE study [Abstract]. Circulation 2002; 106 Suppl. II: 3721

    Google Scholar 

  12. Annemans L, Lindgren P, Frei A, et al. Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis [Abstract]. Eur Heart J 2003; 24 Suppl.: 3002

    Google Scholar 

  13. Lindgren P, Jönsson B, Spiesser J, et al. Short and long term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST-segment elevation (ACS) in Scandinavian countries [Abstract]. Value in Health 2003; 6: 621

    Article  Google Scholar 

  14. Weintraub W, Mahoney EM, Lamy A, et al. Long-term cost effectiveness of platelet inhibition with clopidogrel in patients presenting with acute coronary syndromes: results from the CURE trial [Abstract]. Circulation 2003; 108: 1925

    Google Scholar 

  15. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial. J Intern Med 2004; 255: 562–70

    Article  PubMed  CAS  Google Scholar 

  16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–38

    Article  PubMed  CAS  Google Scholar 

  17. Schwarz B, Lindgren P, Nanz S. Long-term cost-effectiveness of clopidogrel plus acetylsalicylic acid in patients with acute coronary syndrome without ST-segment elevation in Austria [in German]. PharmacoEconomics — German Research Articles 2004; 2: 31–41

    Google Scholar 

  18. Van Hout BA, Tangelder MJD, Bervoets P, et al. Costeffectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands [Abstract]. Value in Health 2003; 6: 667

    Article  Google Scholar 

  19. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458–66

    Article  PubMed  CAS  Google Scholar 

  20. Annemans L, Lindgren P, Frei A, et al. Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions: a five European countries analysis [Abstract]. Eur Heart J 2003; 24 Suppl.: 130

    Google Scholar 

  21. Mehta SR, Weintraub WS, Jonsson B, et al. Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing PCI in the CURE trial: the PCI— CURE economic analysis [Abstract]. J Am Coll Cardiol 2003; 41 suppl. 2: 383A

    Article  Google Scholar 

  22. Spiesser J, Carita P, Annemans L, et al. Economic impact of clopidogrel in patients with acute coronary syndromes without ST-segment elevation (ACS) undergoing percutaneous coronary interventions (PCI): a European review [Abstract]. Value in Health 2003; 6: 651

    Article  Google Scholar 

  23. Mahoney EM, Mehta S, Lamy A, et al. Long-term cost effectiveness of platelet inhibition with clopidogrel in patients undergoing PCI after presenting with an acute coronary syndrome: results from PCI—CURE [Abstract]. Circulation 2003; 108: 2625

    Google Scholar 

  24. Beinart S, Kolm P, Veledar E, et al. Short and long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel following percutaneous coronary intervention: results from CREDO [Abstract]. Circulation 2003; 108: 3495

    Google Scholar 

  25. Brown RE, Henderson RA, Koster D, et al. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. Eur Heart J 2002; 23: 50–8

    Article  PubMed  CAS  Google Scholar 

  26. Jonsson B, Johannesson M, Kjekshus J, et al. Costeffectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001–7

    Article  PubMed  CAS  Google Scholar 

  27. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993; 22: 1697–702

    Article  PubMed  CAS  Google Scholar 

  28. Franzosi MG, Maggioni AP, Santoro E, et al. Costeffectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. PharmacoEconomics 1998; 13: 337–46

    Article  PubMed  CAS  Google Scholar 

  29. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and costeffectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002; 288: 1851–8

    Article  PubMed  Google Scholar 

  30. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000; 101: 366–71

    Article  PubMed  CAS  Google Scholar 

  31. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327: 7–13

    Article  PubMed  CAS  Google Scholar 

  32. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997; 336: 332–6

    Article  PubMed  CAS  Google Scholar 

  33. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141: 727–34

    Article  PubMed  CAS  Google Scholar 

  34. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418–24

    Article  PubMed  CAS  Google Scholar 

  35. Bjorholt I, Andersson FL, Kahan T, et al. The costeffectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. J Intern Med 2002; 251: 508–17

    Article  PubMed  CAS  Google Scholar 

  36. Lindgren P, Fahlstadius P, Hellenius ML, et al. Costeffectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm — a stochastic model of exercise and dietary advice. Prev Med 2003; 36: 403–9

    Article  PubMed  Google Scholar 

  37. Van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat? Eur Heart J 2001; 22: 751–61

    Article  PubMed  Google Scholar 

  38. van Hout B, Tangelder M, Bervoets P, et al. Clopidogrel in patients with myocardial infarction, stroke and peripheral arterial disease in the Netherlands [Abstract]. Value in Health 2003; 6: PCV27

    Google Scholar 

  39. Phillips KA, Shlipak MG, Coxson P, et al. Heath and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 2000; 284: 2748–54

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    William S. Weintraub

  2. Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden

    Bengt Jönsson

  3. Department of Cardiology, Hô pital Cardiologique, Lille, France

    Michel Bertrand

Authors
  1. William S. Weintraub
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bengt Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Bertrand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William S. Weintraub.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weintraub, W.S., Jönsson, B. & Bertrand, M. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events. Pharmacoeconomic 22 (Suppl 4), 29–41 (2004). https://doi.org/10.2165/00019053-200422004-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200422004-00006

Keywords

Search

Navigation